

Quality of adverse event reporting in clinicals trials of COVID-19 drugs : a systematic review

First published: 19/04/2022

Last updated: 21/04/2022

Study

Planned

Administrative details

EU PAS number

EUPAS45959

Study ID

46849

DARWIN EU® study

No

Study countries

France

Study status

Planned

Research institutions and networks

Institutions

Toulouse University Hospital

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

François Montastruc francoismontastruc@hotmail.fr

Study contact

francoismontastruc@hotmail.fr

Primary lead investigator

François Montastruc

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 04/01/2022

Study start date

Planned: 18/04/2022

Date of final study report

Planned: 06/06/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

National Research Agency (NRA)

Study protocol

[Protocole.pdf](#) (217.25 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Main study objective:

the main goal of this systematic review, is to assess the quality of adverse event reporting in clinical trials of COVID-19 drugs

Study Design

Non-interventional study design

Systematic review and meta-analysis

Population studied

Age groups

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Renal impaired

Estimated number of subjects

100

Study design details

Data analysis plan

we will calculate the proportion of monoclonal, antiviral and immunomodulatory antibodies that are of high, moderate, low or very low quality. For the first secondary objective, we will calculate for each drug, the proportion of studies that use "standardized" methods as the double-blind method according to the quality of their reporting of adverse events. i.e. calculate the proportion of studies using the double-blind method in the category of studies with a high, moderate, low and very low score. Finally, for the second secondary objective, we will make a comparison between the serious adverse events reporting in trial articles published and their associated clinical trial summaries. For that, we will calculate the percentage of consistent and different serious adverse events between the two sources.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Conflicts of interest of investigators

[Declaration of Interests-Annex5-i.pdf](#) (86.47 KB)

Composition of steering group and observers

[Composition of Steering Group and ObserversDocument.pdf](#) (46.68 KB)

Signed code of conduct

[Déclaration à signer -signed.pdf](#) (116.04 KB)

Signed code of conduct checklist

[Annexe 2 à signer .pdf](#) (209.61 KB)

Data sources

Data sources (types)

[Published literature](#)

[Other](#)

Data sources (types), other

[The pubMed database](#)

Use of a Common Data Model (CDM)

CDM mapping

[No](#)

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No